igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
Company profile
Ticker
IGC
Exchange
Website
CEO
Ram Mukunda
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
India Globalization Capital, Inc.
SEC CIK
Corporate docs
Subsidiaries
holding company • IGCare, LLC • IGC Pharma, LLC • Holi Hemp, LLC • Sunday Seltzer, LLC • SAN Holdings, LLC • IGC Pharma SAS • Techni Bharathi Private Limited • India Mining and Trading Private Limited • IGC Materials Private Limited ...
IRS number
202760393
IGC stock data
Latest filings (excl ownership)
8-K
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
27 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
424B5
Prospectus supplement for primary offering
21 Mar 24
8-K
Departure of Directors or Certain Officers
13 Mar 24
10-Q
2024 Q3
Quarterly report
14 Feb 24
424B5
Prospectus supplement for primary offering
31 Jan 24
EFFECT
Notice of effectiveness
9 Jan 24
CORRESP
Correspondence with SEC
4 Jan 24
UPLOAD
Letter from SEC
4 Jan 24
S-3
Shelf registration
29 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm | 3.03 mm |
Cash burn (monthly) | (no burn) | 299.75 k | 830.33 k | 912.25 k | 539.33 k | 520.92 k |
Cash used (since last report) | n/a | 1.78 mm | 4.94 mm | 5.43 mm | 3.21 mm | 3.10 mm |
Cash remaining | n/a | 1.24 mm | -1.91 mm | -2.40 mm | -182.48 k | -72.92 k |
Runway (months of cash) | n/a | 4.1 | -2.3 | -2.6 | -0.3 | -0.1 |
Institutional ownership, Q2 2023
4.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 759.54 mm |
Total shares | 2.65 mm |
Total puts | 18.50 k |
Total calls | 44.10 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 755.79 k | $235.50 mm |
Vanguard | 646.54 k | $201.46 mm |
Geode Capital Management | 302.14 k | $94.15 mm |
STT State Street | 184.11 k | $57.37 mm |
Renaissance Technologies | 162.71 k | $51.00 k |
Dearborn Partners | 116.71 k | $36.37 mm |
Susquehanna International | 75.16 k | $23.42 mm |
NTRS Northern Trust | 71.36 k | $22.24 mm |
Bridgeway Capital Management | 69.00 k | $21.50 mm |
GS Goldman Sachs | 65.51 k | $20.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Terry L Lierman | OPTIONS Common Stock | Grant | Acquire A | No | No | 0.3 | 150,000 | 45.00 k | 150,000 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 28,500 | 0.00 | 1,242,917 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 42,750 | 0.00 | 1,214,417 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 100,000 | 0.00 | 1,171,667 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 58,333 | 0.00 | 1,071,667 |
13 Mar 24 | Prins Richard K | Common Stock | Option exercise | Acquire M | No | No | 0 | 100,000 | 0.00 | 1,013,334 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Grant | Acquire A | No | No | 0 | 175,000 | 0.00 | 175,000 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Grant | Acquire A | No | No | 0 | 210,000 | 0.00 | 210,000 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 71,250 | 0.00 | 213,750 |
13 Mar 24 | Prins Richard K | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 100,000 | 0.00 | 200,000 |
News
'GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties' - Marijuana Moment
27 Mar 24
IGC Pharma Announces $3M Unregistered Private Placement Of 8,823,529 Shares Of Its Common Stock
26 Mar 24
'Three In Five Americans Want Congress To Pass Marijuana Banking Reform, American Bankers Associations Poll Finds Amid Renewed Push' - Marijuana Moment
25 Mar 24
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
20 Mar 24
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
20 Mar 24
Press releases
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
26 Mar 24
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
20 Mar 24
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
12 Mar 24
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
28 Feb 24
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target
23 Feb 24